Salem Eid Salem

Salem Eid Salem

Auto-generated profile, based on publicly available information

Salem Eid Salem

Department of Medical Oncology, National Cancer Institute (NCI), Cairo University, Cairo, Egypt

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AZAbdel Rahman N. Zekri:
Abdel Rahman N. Zekri:
AYAmira Salah El-Din Youssef
Amira Salah El-Din Youssef
MLMai Lotfy
Mai Lotfy
RGReham Gabr
Reham Gabr
OAOla S Ahmed
Ola S Ahmed
ABAbeer A Bahnassy
Abeer A Bahnassy
The study was designed to assess the possibility of using circulating miRNAs (serum miRNAs) as diagnostic biomarkers in colorectal cancer (CRC) and to identify their possibility as candidates for targeted therapy. The study involved two sample sets: 1- a training set which included 90 patients with colorectal related disease (30 with CRC, 18 with inflammatory bowel disease (IBD), 18 with colonic polyps (CP) and 24 with different colonic symptoms but without any colonoscopic abnormality who were enrolled as control group) and 2- a validation set which included 100 CRC patients. Serum miRNAs were extracted from all subjects to assess the expression profiles for the following miRNAs (miR-17, miR-18a, miR-19a, miR-19b, miR-20a, miR-21, miR-146a, miR-223, miR-24, miR-454, miR-183, miR-135a, miR- 135b and miR- 92a) using the custom miScript miRNA PCR-based sybergreen array. The area under the receiver operating characteristic curve (AUC) was used to evaluate the diagnostic performance of the studied miRNAs for colorectal cancer diagnosis. Data analysis of miRNA from the training set showed that; compared to control group, only miR-19b was significantly up-regulated in patients with IBD group (fold change = 5.24, p = 0.016), whereas in patients with colonic polyps, miR-18a was significantly up-regulated (fold change = 3.49, p-value = 0.018). On the other hand, miR-17, miR-19a, miR-20a and miR-223 were significantly up-regulated (fold change = 2.35, 3.07, 2.38 and 10.35; respectively and p-value = 0.02, 0.015, 0.017 and 0.016; respectively in CRC patients. However, the validation set showed that only miR-223 was significantly up-regulated in CRC patients (fold change = 4.06, p-value = 0.04). Aberrant miRNA expressions are highly involved in the cascade of colorectal carcinogenesis. We have found that (miR-17, miR-19a, miR-20a and miR-223) could be used as diagnostic biomarkers for CRC. On the other hand, miR-19b and miR-18a could be used as diagnostic biomarkers for CP and IBD respectively.

1 March 2014 in Journal of the Egyptian National Cancer Institute
Verified
Journal Article
Open access
NANelly Alieldin
Nelly Alieldin
OAOmnia M. Abo-Elazm
Omnia M. Abo-Elazm
DBDalia Bilal
Dalia Bilal
SSSalem Eid Salem
Salem Eid Salem
EGEman Gouda
Eman Gouda
AIAmal S. Ibrahim
Amal S. Ibrahim
Objective: Primary objective was to verify whether breast cancer patients aged less than 40 years at diagnosis have poorer prognosis than older patients. Secondary to assess prognostic factors influencing disease free survival. Methods: 941 women were diagnosed with non-metastatic breast cancer at NCI, Cairo in 2003. Epidemiologic, clinico-pathological characteristics, treatment modalities and disease free survival were compared among the two age groups. Prognostic factors were evaluated for association with disease-free survival. Results: One hundred-eighty-one patients (19.2%) were younger than 40 years and 760 (80.8%) were older. Older women presented with higher rates of comorbidities and younger women presented with more hormone non-responsive tumors. Young women presented with larger tumors pT4 = 13.8% compared to 8.6% in older women, yet not significant. Young women were treated with more conservative surgery, more adjuvant chemotherapy and radiotherapy while older women with more radical mastectomies and more hormonal treatment. Recurrence rates were significantly higher among young women 44.2% compared to 34.5% in older women. Five year disease free survival in young women was 38.9% +/- 4.6% compared to 48.6% +/- 2.5% with adjusted hazard ratio of 1.22 95% CI (0.91-1.64), p = 0.19. Multivariate analyses identified positive axillary lymph nodes (pN2-pN3), larger tumor size (pT3-pT4), hypertension, lobular carcinoma type and lack of adjuvant systemic treatment as independent factors associated with poor DFS. Conclusion: Young women were not found to have poorer prognosis, yet they presented with more ER negative tumors. Most of women presented with advanced stage and young women had higher recurrence rates. (C) 2013 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.

22 July 2010 in Cancer
Verified
Journal Article
Closed access
PDF file
MEMostafa M. El‐Serafi
Mostafa M. El‐Serafi
ABAbeer A. Bahnassy
Abeer A. Bahnassy
NANasr M. Ali
Nasr M. Ali
SESalem M. Eid
Salem M. Eid
MKMahmoud M Kamel
Mahmoud M Kamel
AZAbdel Rahman N. Zekri:
Abdel Rahman N. Zekri:

1 March 2024 in JCO Global Oncology
Verified
Journal Article
Open access
NRNoha Rashad
Noha Rashad
SSSalem Eid Salem
Salem Eid Salem
MMMohamed A.M. Meheissen
Mohamed A.M. Meheissen
GRGhada Refaat
Ghada Refaat
HSHeba Mahmoud Sami
Heba Mahmoud Sami
EDEman D. El Desouky
Eman D. El Desouky
PURPOSE: Early-onset colorectal cancer (EOCRC) is a rising health problem. The incidence of EOCRC has increased over the past 2 decades all over the world. Reports from Egypt since the 1990s have reported a higher incidence among young populations with no identifiable risk factors. The aim of this study was to assess EOCRC in Egypt regarding incidence, characteristics, treatment pattern, and survival compared with average age onset and elderly patients. MATERIALS AND METHODS: This was a retrospective, record-based, cohort study combining data from four different cancer centers in Egypt. We grouped patients according to age into three categories: the EOCRC group for patients age ≤45 years and the average age onset and elderly cancer group (for patients age ≥65 years). RESULTS: The study included 1,310 patients with histopathologically proven colorectal cancer, representing four different geographical areas in Egypt. Patients with EOCRC represented 42.4% of the study population. Female patients were 50.6% among the EOCRC group and 52.5% among the average age group. Rectal tumors were significantly higher in EOCRC (54.7% v 40.6%; P < .001). There was no significant difference between both groups regarding the tumor stage at presentation, obstruction, or presence of metastases at presentation. Patients with EOCRC had a significantly higher rate of peritoneum/adnexa metastases than the average age ones (12.3% in EOCRC v 6.9% in the average age group; P < .001). No statistically significant differences between EOCRC and average age groups in both disease-free survival and overall survival were reported. CONCLUSION: A comprehensive framework for the study of EOCRC is required in Egypt as well as a genomic analysis to identify possible underlying genetic alterations responsible for the high incidence of EOCRC.

20 April 2011 in Biomarkers
Verified
Journal Article
Closed access
PDF file
HTH.M. El Tayebi
H.M. El Tayebi
WSW. Salah
W. Salah
ISI.H. El Sayed
I.H. El Sayed
AZAbdel Rahman N. Zekri:
Abdel Rahman N. Zekri:
NZN. Zayed
N. Zayed
AAAhmed Ihab Abdelaziz
Ahmed Ihab Abdelaziz
Background/aim: Elevated relative expression of insulin-like growth factor-II (IGF-II) was observed in hepatocellular carcinoma (HCC) liver tissues with a role in neovascularization and associated with poor prognosis. IGF-II is influenced by the proteolytic cleavage of IGF-binding protein 3 and by matrix metalloproteinases (MMP), which are further regulated by their tissue inhibitors tissue inhibitor of metalloprotienase-1 (TIMP-1). Our aim is to study new molecular markers for HCC. Patients/methods: RNA was extracted from the peripheral blood for evaluating the relative expression of IGF-II, MMP-9, and TIMP-1 in correlation with clinical staging of 39 HCC patients and 15 healthy controls using TaqMan real-time PCR. Results: The relative expression of IGF-II and MMP-9 mRNA were significantly elevated in HCC patients compared with healthy controls; P-value <0.0001 for both. There was a significant correlation between MMP-9 and different HCC stages. On the other hand, TIMP-1 was significantly down-regulated in HCC patients; P = 0.0003 with the elevation of the IGF-II/TIMP-1 ratio. Significant correlation between TIMP-1 and HCC Stage III and Stage IV was found; P-value = 0.0138. Conclusion: These results highlight the importance of profiling the expression of IGF-II, MMP-9, and TIMP-1 in the peripheral blood as prognostic molecular biomarkers in HCC.

1 February 2017 in Experimental and Molecular Pathology
Verified
Journal Article
Closed access
AKAmira B. Kassem
Amira B. Kassem
SSSalem Eid Salem
Salem Eid Salem
MAMohamed Abdelrahim
Mohamed Abdelrahim
ASAmira S.A. Said
Amira S.A. Said
Ahmad SalahuddinAhmad Salahuddin
Ahmad Salahuddin
ABAbeer A. Bahnassy
Abeer A. Bahnassy